1 Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN

2 pathway in Alzheimer's disease pathogenesis

- 3
- 4 Matthew Bracher-Smith, PhD¹, Ganna Leonenko, PhD², Emily Baker, PhD², Karen Crawford, MSc¹,
- 5 Andrew C. Graham, MSc³, Dervis A. Salih, PhD³, Brian W. Howell, PhD⁴, John Hardy, PhD^{3*}, Valentina
- 6 Escott-Price, PhD^{1,2*}
- 7
- 8 Affiliations
- 9 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine &
- 10 Clinical Neurosciences, Cardiff University, UK
- 11 2 Dementia Research Institute, Cardiff University, UK
- 12 3 Dementia Research Institute, University College London, UK
- 13 4 Neuroscience and Physiology, State University of New York, USA
- 14
- 15 Corresponding Authors
- 16 Valentina Escott-Price
- 17 Tel. +44 2920 688429
- 18 Address: Hadyn Ellis Building, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK
- 19 e-mail: escottpricev@cardiff.ac.uk
- 20
- 21 John Hardy
- 22 Tel. +44 2031 086802
- 23 Address: UCL Cruciform Building, Gower Street, London, WC1E 6BT, UK
- 24 e-mail: j.hardy@ucl.ac.uk
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

| 27 | The APOE- ϵ 4 allele is known to predispose to amyloid deposition and consequently is |
|----|---|
| 28 | strongly associated with Alzheimer's disease (AD) risk. There is debate as to whether the |
| 29 | APOE gene accounts for all genetic variation of the APOE locus. Another question which |
| 30 | remains is whether APOE- ϵ 4 carriers have other genetic factors influencing the progression |
| 31 | of amyloid positive individuals to AD. We conducted a genome-wide association study in a |
| 32 | sample of 5,390 APOE- ϵ 4 homozygous (ϵ 4 ϵ 4) individuals (288 cases and 5,102 controls) |
| 33 | aged 65 or over in the UK Biobank. We found no significant associations of SNPs in the APOE |
| 34 | locus with AD in the sample of ϵ 4 ϵ 4 individuals. However, we identified a novel genome- |
| 35 | wide significant locus associated to AD, mapping to DAB1 (rs112437613, OR=2.28, CI=1.73- |
| 36 | 3.01, $p=5.4 \times 10^{-9}$). This identification of <i>DAB1</i> led us to investigate other components of the |
| 37 | DAB1-RELN pathway for association. Analysis of the DAB1-RELN pathway indicated that the |
| 38 | pathway itself was associated with AD, therefore suggesting an epistatic interaction |
| 39 | between the APOE locus and the DAB1-RELN pathway. |
| | |

41 Introduction

| 42 | Genome wide association studies (GWAS) have led to the identification of many genetic loci |
|----|--|
| 43 | influencing the risk of dementia [1]. However, none of these approach the importance of |
| 44 | the APOE locus [2] where the APOE- ϵ 4 allele has a frequency of ~15% in controls and has a |
| 45 | risk ratio of >3 in cases. Other loci with allele frequencies of >1% have risk ratios of <1.4. |
| 46 | Recent studies have shown that the APOE genotype is almost solely responsible for amyloid |
| 47 | deposition whereas other components of Alzheimer's disease (AD) genetic risk contribute to |
| 48 | the occurrence of dementia in the context of amyloid deposition [3]. Furthermore, |
| 49 | neuropathologic studies have shown that clinical diagnoses in Alzheimer series had a |
| 50 | diagnostic accuracy of around 80%: this accuracy is implied by analyses comparing the large |
| 51 | clinical GWAS with the smaller neuropathologic GWAS, leading to the concern that these |
| 52 | larger GWAS are contaminated by other diagnoses. This concern is heightened by the |
| 53 | reports of loci for frontotemporal dementia in case series labelled as Alzheimer's disease in |
| 54 | the most recent GWAS for the disorder [4]. |
| 55 | |
| 56 | With this background, we have undertaken an AD GWAS in individuals who are APOE- ϵ 4 |
| 57 | homozygotes for three reasons. First, because in this group diagnostic accuracy is very high; |
| 58 | second, to assess whether in this context there is additional genetic risk at the APOE locus; |
| 59 | and third, to assess which previously reported loci are replicated in these cases and whether |
| 60 | there are any novel loci we can identify which are dependent on APOE- ϵ 4 homozygosity. |
| 61 | This study was possible in the UK Biobank [5] because it has a very large cohort, with a |
| 62 | sufficient number (for statistical analyses) of APOE- ϵ 4 homozygotes, where many |
| 63 | participants are now reaching the age where they are at risk. |

64 Here we report that the APOE allele alone accounts for the AD risk in the LD block on 65 chromosome 19 in the European population. Furthermore, in APOE- ϵ 4 homozygotes, we 66 identify AD risk associated with the DAB1 gene that encodes a synapse regulatory protein. 67 Subsequent analyses revealed a gene set association with the DAB-RELN pathway. 68 69 Methods 70 Phenotypes 71 Individuals from the UK Biobank were considered if they self-reported as white British and 72 were of similar genetic ancestry by principal component analysis (UK Biobank field 22006), 73 were unrelated (kinship coefficient < 0.04) and if they had not withdrawn consent to 74 participate under UK Biobank. Participants were further excluded if they showed excessive 75 missingness or sex chromosome aneuploidy, were outliers for heterozygosity, had 76 mismatching self-reported and inferred sex from genotyping data, and had over 10 putative 77 third-degree relatives. AD definition was derived using ICD-10 codes in hospital and death 78 records. Individuals were coded as cases where dementia in Alzheimer's disease (ICD-10 79 code F00) or Alzheimer's disease (code G30) were present. Controls were defined as those 80 without F00, G30, vascular dementia (F01), dementia in other diseases (F02) and 81 unspecified dementia (F03). APOE status was assigned to each individual, as defined by SNPs 82 rs7412 and rs429358 which are both present on the Affrymetrix Axiom genotyping array 83 used. After quality control and restriction to APOE-E4 homozygous individuals aged 65 or 84 over, 288 cases and 5,102 controls were included in analysis. 85

86 Genetic quality control

| 87 | The UK Biobank genetic data from the haplotype reference consortium (HRC), imputed by |
|-----|---|
| 88 | the UK Biobank [6], was restricted to biallelic SNPs (minor allele frequency > 0.05) with |
| 89 | Hardy-Weinberg equilibrium > 10 ⁻⁶ , INFO>0.4 and posterior probability>0.4. After quality |
| 90 | control, 5,349,830 SNPs were included in analysis. |
| 91 | |
| 92 | Analysis |
| 93 | Association analysis was conducted in PLINK2 [7] on UK Biobank dosage data using most |
| 94 | recently recorded age, sex and the first 15 principal components (field 22009) as covariates. |
| 95 | The significant findings (with the logistic regression) were further tested with Cox |
| 96 | proportional-hazards regression (while controlling for the covariates) where the censoring |
| 97 | occurred when a participant reported AD, allowing for the fact that some individuals have |
| 98 | not reached the age at onset and may develop the disease given time. |
| 99 | |
| 100 | The enrichment analysis of significant SNPs (at 5% significance level) or for SNPs showing |
| 101 | the same direction of the effect (assuming that the chance to have the same direction of |
| 102 | effect is 50%) was performed with binom.test() function in R. |
| 103 | |
| 104 | The power calculations were performed with qnorm() function in <i>R</i> -statistical package at |
| 105 | nominal 5% significance level (unless specified otherwise), where Z-score was estimated as |
| 106 | log(OR)/var with the log(OR) as reported in the GWAS. In the Wightman et al. study [4], the |
| 107 | largest OR was selected from the reported ORs in the list of contributing studies. The |
| 108 | variance estimated as the inverse variance, with allele frequencies in cases and controls |

| 109 | (corresponding to the SNP OR), and the sample size as in our study (N cases = 288, N |
|-----|---|
| 110 | controls = 5,102). Plots of regional associations were created using LocusZoom [8]. |
| 111 | |
| 112 | Epistasis was defined as deviation from joint two SNPs linear effects in the logistic |
| 113 | regression model (known as statistical interaction). Significance of the interaction term was |
| 114 | assessed usingepistasis option PLINK [7], accounting for the same covariates as above. The |
| 115 | interaction plots were produced using matplotlib in python [9]. |
| 116 | |
| 117 | Gene-based analysis was run by MAGMA using FUMA v1.3.7 [10, 11]. Competitive setting of |
| 118 | MAGMA was also used to test the candidate pathways for the enrichment of AD significant |
| 119 | genes as compared to the rest of the genome. |
| 120 | |
| 121 | DAB1-RELN pathway analysis |
| 122 | The canonical Reelin-Dab1 signalling pathway has been studied extensively in mouse |
| 123 | neurons and brain [12]. For analysis, we divided the pathway into three sections: a) the |
| 124 | receptor complex, (Reelin, the receptors ApoER2, VLDLR, the adaptor protein DAB1, and the |
| 125 | tyrosine kinases SRC, FYN and YES) [13–16], b) branch 1 that regulates N-cadherin (CRK, |
| 126 | CRKL, C3G, RAP1, P120 catenin, N-cadherin) [17–19] and c) branch 2 that is involved in |
| 127 | microtubule-associated protein tau (MAPT) phosphorylation (PI3K, PDK, AKT, GSK3, STK25) |
| 128 | [20–22]. We converted these mouse proteins to the homologous human genes with the |
| 129 | BioConductor function in R and the NCBI database (www.ncbi.nlm.nih.gov/) yielding: a) |

- 130 RELN, LRP8, VLDLR, DAB1, SRC, FYN, YES1, b) CRK, CRKL, RAPGEF1, RAP1A, CTNND, CDH2, c)
- 131 *PIK3CA, PDK1, PDK2, GSK3B, AKT1, STK25.*
- 132
- 133
- 134 Results
- 135 We present the results in the following order: (a) analysis of the APOE locus, (b) analysis of
- 136 other previously reported GWAS in these cases, (c) identification of the DAB1 locus as a
- 137 genome wide for disease, (d) assessment of other loci in the same DAB1-RELN pathway.
- 138
- 139 APOE locus
- 140 No suggestive variants were identified in the APOE gene or surrounding region
- 141 (chromosome 19: 44.5-46.5 Mb, as defined previously [23]) with the lowest *p*-value at 0.003
- 142 within 1Mb of the APOE gene (Supplementary Figure S1) in APOE-ε4 homozygotes.
- 143
- 144 Other GWAS Hits
- 145 Loci previously reported as GWAS for association with Alzheimer's disease status did not
- 146 show a strong replication in the current analysis of *APOE*-ε4 homozygotes only
- 147 (Supplemental Table S1). Though the power to detect the GWAS-reported effect sizes in this
- sample is not sufficient (see last column of Supplemental Table S1), four loci in CD33
- 149 (p=0.004), IQCK (p=0.009), LILRB2 (p=0.005) and SORL1 (p=0.007, MAF=0.04) had the
- 150 strongest evidence for association in the current analysis and a consistent direction of effect
- 151 between the current and previous GWAS. Weaker but nominally significant associations
- 152 with the consistent direction of the effect were also observed in the APH1B (p = 0.024), BIN1

| 153 | (p=0.011), SEC61G (p=0.015) and SNX1 (p=0.048) genes. In total, eight out of 77 SNPs |
|-----|--|
| 154 | (previously reported as genome-wide significant and available in our study), replicated at |
| 155 | 0.05 significance level with the same direction of association, which is statistically greater |
| 156 | than chance (p=0.038). In addition, 53/77 (69%) SNPs have same direction of effect in the |
| 157 | current analysis and previous GWAS which is greater than expected by chance (p = 0.001). |
| 158 | |
| 159 | Identification of DAB1 as a locus |
| 160 | Multiple novel genome-wide significant intronic SNPs were present in DAB1 (lead SNP: |
| 161 | rs112437613, OR=2.28, CI=1.73-3.01, <i>p</i> =5.36x10 ⁻⁹ ; Figure 1 and Supplemental Figure S2, |
| 162 | Table 1). The minor allele T was associated with disease risk (MAF=6% in non-AD and 12% in |
| 163 | AD $\epsilon 4\epsilon 4$ -participants of the UK Biobank). To allow for the fact that some individuals might |
| 164 | not have reached the age at onset, we fit a survival regression model (adjusting for PCs and |
| 165 | sex). The result remained highly significant (Hazard Ratio=2.27, CI=1.75-2.95, p= 7.8x10 ⁻¹⁰). |
| 166 | The Kaplan-Meier graph (Figure 2) demonstrates that probability of getting the disease (y- |
| 167 | axis) earlier (x-axis) is higher as the number of the risk alleles of rs112437613 SNP increases. |
| 168 | |
| 169 | The frequency of this allele is reported 4%-7% in European population cohorts |
| 170 | (1000Genomes, TOPMED, GnomAD, Estonian, ALSPAC-UK, TWINSUK, Northern Sweden, see |
| 171 | https://genome.ucsc.edu). However, this SNP (and others in LD with it) did not show even a |
| 172 | nominal association to AD in recent GWAS that did not preselect for the $\epsilon4\epsilon4$ genotype: e.g. |
| 173 | a study of 21,982 cases and 41,944 controls the p-values were p~0.5 (see Table 1) [24]. |
| 174 | Indeed, in a case/control sample (without screening for the APOE- ϵ 4 status), the effect size |
| 175 | of this SNP would be OR=1.016, as the proportion of cases, with both T allele of |
| 176 | rs112437613 and $\epsilon 4\epsilon 4$, is 0.016 (=MAF($\epsilon 4$) ² *MAF(rs112437613 in $\epsilon 4\epsilon 4$) = 0.36 ² *0.12, where |

| 177 | 0.36 is the ϵ 4 allele frequency in cases [25], and, similarly, of controls is 0.001. Therefore, |
|-----|---|
| 178 | the frequencies of the T allele in the overall sample are expected to be 0.061 in cases and |
| 179 | 0.06 in controls, and consequently, the power to detect it with the sample size of the [24] |
| 180 | study is close to 0 (\sim 3x10 ⁻⁷). |
| 181 | |
| 182 | This observation led us to test for an epistatic effect in the whole sample of the UK Biobank |
| 183 | aged 65+ (N=229,748). There was indeed significant epistasis between the two loci |
| 184 | (p=1.5x10 ⁻⁵), whereas the effect of the T allele (rs112437613) was positive (OR=1.16, |
| 185 | SE=0.11), but only nominally significant (p=0.021), providing evidence for cooperation |
| 186 | between these two loci. The risk allele frequencies in this locus depending on APOE and AD |
| 187 | status are shown in Table S2 and the risk of AD, depending on the genotypes at the two loci, |
| 188 | is shown in Figure 5. The figure and table clearly show a statistical epistatic effect, where |
| 189 | the disease risk is only visible in people with $\epsilon4\epsilon4$ genotypes. |
| 190 | |
| 191 | Candidate analysis of other loci in the Reelin-DAB1 pathway |
| 192 | Dab1 encodes a cytoplasmic signalling adaptor that is predominantly expressed in neurons |
| 193 | where it acts downstream of the extracellular ligand Reelin to regulate brain lamination |
| 194 | during development [26–29]. Since Reelin-DAB1 signalling also performs an important role |
| 195 | in the adult brain by promoting excitatory synapse maturation [30, 31] and modulating |
| 196 | synaptic plasticity, learning and memory [32–35], we explicitly looked at the SNPs |
| 197 | associations in the <i>RELN</i> gene (chr7:103,112,231-103,629,963). This gene is comprised of |
| 198 | 2002 SNPs and the most significant SNP was rs171331137 (chr7:103479651) with OR=1.51 |
| 199 | (SE=0.11), p=2.4x10 ⁻⁴ (Supplemental Figure S3). Similar to <i>DAB1</i> , we tested this SNP for |

interaction with *APOE*- ε 4 in the whole UK Biobank sample. The interaction term was not significant (p=0.24), however the pattern of AD risk based on the pair of these markers was similar to *DAB1* (Supplemental Figure S4).

203

| 204 | The Reelin ligand and DAB1 adaptor proteins are bridged by two partially redundant |
|-----|--|
| 205 | transmembrane receptors APOER2 (LRP8) and VLDLR [15, 16]. Reelin binding to its receptors |
| 206 | recruits DAB1 to their cytoplasmic tails activating the SRC family kinases, SRC, FYN and YES |
| 207 | [13, 14, 36]. This leads to the increased tyrosine phosphorylation of DAB1 and the |
| 208 | recruitment of additional signalling adaptor proteins that activate two key branches of the |
| 209 | pathway (Figure 6). One branch is initiated by the binding of CRK and CRKL to phospho- |
| 210 | DAB1, leading to the phosphorylation of C3G (RAPGEF1) and activation of RAP1 (RAP1A) [17, |
| 211 | 18]. This leads to the upregulation of N-Cadherin (CDH2) cell-surface expression through |
| 212 | engagement with p120 catenin (CTNND) [19]. A second branch is regulated by the binding |
| 213 | of phosphatidylinostiol 3-kinase (PIK3KA) to DAB1 leading to the activation of PDK (PDK1, |
| 214 | PKD2) and AKT (AKT1) ultimately suppressing the activity of the MAPT kinase GSK3 [20]. In |
| 215 | mouse, deficiency of DAB1 has been shown to augment tau-phosphorylation and Stk25 has |
| 216 | been implicated in this process [21, 22]. Since the signalling complex and the downstream |
| 217 | pathways have potential significance in the development of AD, we tested their associated |
| 218 | genes for enrichment in AD. |
| 219 | |
| | |

Using the results of the gene-based analyses described above, we tested whether the receptor complex and the two pathway branches contained significantly more AD associated genes as compared with the rest of the genome. We found that they were

| 223 | significantly (or almost significantly) enriched for genes associated to AD in the APOE- ϵ 4 |
|-----|---|
| 224 | homozygotes (p-values 0.06, 0.009, 0.075, for the receptor complex and branches 1 and 2, |
| 225 | respectively). The strongest significance was achieved when we combined the receptor |
| 226 | complex and the two branches of the pathway (p=0.0055). Table 2 shows the details for |
| 227 | each gene. |
| 228 | |
| 229 | Discussion |
| 230 | No residual association at the APOE locus |
| 231 | APOE- ϵ 4 is the strongest genetic risk factor for late onset AD. APOE- ϵ 4 carriers have |
| 232 | elevated risk for AD and earlier age-at-onset, with APOE- ϵ 4 homozygotes at the highest risk |
| 233 | [37, 38]. Many loci beyond APOE have been reported as associated with disease in |
| 234 | increasingly large GWAS and meta-analyses, with over 80 susceptibility loci reported |
| 235 | collectively [4, 39, 40]. We find no evidence to support the role of additional loci in an |
| 236 | extended 2Mb region around APOE in APOE-ɛ4 homozygotes. This is supported by previous |
| 237 | work on risk in the APOE region after adjusting for number of ϵ 4 alleles [41, 42]. It is |
| 238 | therefore unlikely that variants contribute additional risk to AD in the APOE region in APOE- |
| 239 | $\epsilon 4$ homozygotes although association has previously been reported in PVRL2 and APOC1 in |
| 240 | Chinese samples after adjusting for number of <i>APOE</i> -ε4 alleles [43]. Variants around <i>APOE</i> |
| 241 | may explain additional variation in risk in populations where polymorphisms are in less |
| 242 | pronounced LD with rs429358, and residual variability in APOE- ϵ 3 carriers may still modify |
| 243 | risk for the disease [44]. |
| | |

244

245 Other established GWAS hits

This study does not have statistical power to reliably determine whether all the previously
reported GWAS hits are associated with disease in *APOE*-ε4 homozygotes or whether those
which do show direct evidence for association (nominal significance) are grouped in any
particular pathway.

250

251 Association with DAB1

252 Putative novel risk SNPs with strong evidence for association were mapped to the DAB1 253 gene on chromosome 1. Roles for DAB1 and RELN have previously been suggested in AD 254 primarily based on studies in mice [36, 45–48] and functional genomic analysis in humans 255 [49], but genome-wide association in humans has been lacking. However, it has been shown 256 that the expression of DAB1 and RELN are altered in AD brains [50–52]. DAB1 interacts with 257 Asp-Pro-any residue-Tyr (NPXY) motifs in the cytoplasmic domains of amyloid precursor 258 protein (APP) as it does with similar motifs in the cytoplasmic tails of the Reelin receptors 259 through its N-terminal PTB domain [53, 54]. The NPXY motif is required for APP 260 internalization and its deletion reduces A β production [55]. DAB1 association with APP has 261 been shown to reduce amyloidogenic processing [36], which suggests it is involved in the 262 intracellular trafficking of APP. Reelin also reduces Aβ production in HEK293 cells that don't 263 express DAB1 [47]. In a mouse model of AD, heterozygosity of *Reln* increases the 264 accumulation of A β plaques [45], suggesting that the pathway physiologically alters APP 265 cleavage in a manner that would protect against AD. In addition, homozygous loss-of-266 function in *Reln* and *Dab1* have been shown to augment tau-phosphorylation [21]. Reelin 267 overexpression reduces abnormal somatodendritic localization of phosphor-Tau, A^β plaques 268 and synaptic loss in AD model mice [46, 48]. Thus there are links between the Reelin-DAB1

pathway and the two major pathological features of AD. In this study, both examined
branches of the *DAB1-RELN* pathway had genes with significant association with AD. SNPs
near *RAP1A* were significant; however, it remains to be determined if this branch regulates
Aβ phosphor-Tau or another AD related pathology. The other major pathway downstream
of Reelin-DAB1 has been associated with tau-phosphorylation and both *AKT* and *PIK3KA*from this branch were significantly associated with AD.

275

276 The dependence of the association between DAB1/RELN and AD on APOE-E4 homozygosity 277 is intriguing since there are several links between the Reelin pathway and APOE. The Reelin 278 receptors are also APOE receptors and DAB1 binds the NPXY motifs in the cytoplasmic tails 279 of other LDL-superfamily receptors [53, 54, 56], such as LDL-receptor related protein 1 that 280 has roles in APOE/A β internalization and clearance [57]. Recent studies show that APOE- ϵ 4 281 reduces recycling of ApoER2 back to the plasma membrane making the cells less responsive 282 to Reelin [58] and that Reelin protects against the toxic effects of A β on synapses [59]. Thus 283 in APOE- ε 4 homozygotes, one can imagine a threshold effect with high APOE- ε 4 driving a 284 pathological cycle by reducing the effects of DAB1 and RELN signalling including its normal 285 function to reduce A β production/toxicity and/or MAPT-phosphorylation.

286

287 While the effect the SNPs have on the function of *DAB1* or other pathway genes remain to 288 be determined, based on previous studies it would seem likely that they cause a partial loss-289 of-function that is potentially age dependent or cell-type specific in nature and would result 290 in altered expression (eQTL) or splicing (sQTL). More than partial disruption of activity would 291 likely lead to a developmental disorder in the homozygous individuals similar to loss-of-

292 function alleles for Dab1 in mice and RELN in humans and mice [60]. The significant SNPs 293 identified here fall in intron 2 and are found in 4-7% of the population. Interestingly DAB1 294 exomic variation is constrained and few variants are more prevalent than 1-2% (GnomAD) 295 suggesting that the identified SNPs do not flag an alteration in the DAB1 coding sequence. 296 DAB1 is alternatively spliced and differentially expressed most notably in a cell-type specific 297 manner [26, 61–63]. Alternative splicing has been shown to regulate exons encoding a 298 subset of the phosphorylation sites and a C-terminal exon altering Dab1 functionality in 299 mice. We note that humans have a read through variant of exon 3 that would lead to 300 transcriptional termination 14 residues later (variant 9) that has not been identified in mice. 301 It encodes the first part of the phosphotyrosine binding (PTB) domain residues 37-69, but it 302 is likely to be functionally inert since the PTB domain extends to residue 171 [64]. With this 303 complexity and the size of the DAB1 gene, over 1 Mb, it could take significant effort to 304 dissect the consequence of the SNPs identified here on gene function and AD. 305 306 In conclusion, we find a novel genome-wide significant hit in DAB1 in an APOE-E4 307 homozygote AD GWAS. This seems to be a hit only in APOE- ε 4 homozygotes. Furthermore, 308 it seems that this association marks a more general importance of the DAB1-RELN pathway 309 in disease pathogenesis. It is not clear why this pathway should be of such importance in 310 APOE- ε 4 homozygotes only, but a clue may be that such individuals have particularly dense 311 AB pathology and one can imagine that this pathway either has a role in modulating APP 312 processing or in driving tau-phosphorylation in a manner that is dependent on high AB 313 levels. This work suggests that DAB1 has a protective role in late onset AD and highlights the 314 importance of resolving the mechanism that likely involves the REELIN-DAB1 pathway for

315 therapeutic development.

316

317 Funding

- 318 This work was largely funded by the UK DRI, which receives its funding from the DRI Ltd,
- 319 funded by the UK Medical Research Council (UKDRI-3003), Alzheimer's Society and ARUK. JH
- 320 is supported by the Dolby Foundation, and by the National Institute for Health Research
- 321 University College London Hospitals Biomedical Research Centre. D.A.S. also received
- 322 funding from the Alzheimer's Research UK (ARUK) pump priming scheme via the UCL
- 323 network. VEP is supported by Joint Programming for Neurodegeneration (JPND) (MRC:
- 324 MR/T04604X/1).

325

Competing interests

327 The authors report no competing interests.

328 References

- 1. Hardy J, Escott-Price V. Genes, pathways and risk prediction in Alzheimer's disease.
- 330 Hum Mol Genet 2019; 28: R235–R240.
- 331 2. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson J V., Lince DH, et al. A High-
- 332 Density Whole-Genome Association Study Reveals That APOE Is the Major
- 333 Susceptibility Gene for Sporadic Late-Onset Alzheimer's Disease. J Clin Psychiatry
- 334 2007; 68: 0–0.
- 335 3. Leonenko G, Shoai M, Bellou E, Sims R, Williams J, Hardy J, et al. Genetic risk for
- 336 alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol
- 337 2019; 86: 427–435.
- 338 4. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A
- 339 genome-wide association study with 1,126,563 individuals identifies new risk loci for
 340 Alzheimer's disease. Nat Genet 2021 539 2021; 53: 1276–1282.
- 5. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
- 342 Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of
- 343 Middle and Old Age. PLOS Med 2015; 12: e1001779.
- 6. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
- resource with deep phenotyping and genomic data. Nature 2018; 562: 203–209.
- 346 7. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 347 PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7.
- 348 8. Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al.
- 349 LocusZoom.js: interactive and embeddable visualization of genetic association study
- 350 results. Bioinformatics 2021; 37: 3017–3018.
- 351 9. Hunter JD. Matplotlib. Comput Sci Eng 2007; 9: 90–95.

- 352 10. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set
- 353 Analysis of GWAS Data. PLoS Comput Biol 2015; 11.
- 11. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
- annotation of genetic associations with FUMA. Nat Commun 2017 81 2017; 8: 1–11.
- 12. Lee GH, D'Arcangelo G. New insights into reelin-mediated signaling pathways. Front
- 357 Cell Neurosci 2016; 10: 122.
- 358 13. Arnaud L, Ballif BA, Förster E, Cooper JA. Fyn Tyrosine Kinase Is a Critical Regulator of
- 359 Disabled-1 during Brain Development. Curr Biol 2003; 13: 9–17.
- 360 14. Bock HH, Herz J. Reelin Activates Src Family Tyrosine Kinases in Neurons. Curr Biol
 361 2003; 13: 18–26.
- 362 15. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin Is a
 363 Ligand for Lipoprotein Receptors. Neuron 1999; 24: 471–479.
- 16. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, et al.
- 365 Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine
- 366 Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation. Neuron 1999; 24:
 367 481–489.
- 368 17. Ballif BA, Arnaud L, Arthur WT, Guris D, Imamoto A, Cooper JA. Activation of a
- 369 Dab1/CrkL/C3G/Rap1 Pathway in Reelin-Stimulated Neurons. Curr Biol 2004; 14: 606–
 370 610.
- 371 18. Franco SJ, Martinez-Garay I, Gil-Sanz C, Harkins-Perry SR, Müller U. Reelin Regulates
- 372 Cadherin Function via Dab1/Rap1 to Control Neuronal Migration and Lamination in
 373 the Neocortex. Neuron 2011; 69: 482–497.
- Jossin Y, Cooper JA. Reelin, Rap1 and N-cadherin orient the migration of multipolar
 neurons in the developing neocortex. Nat Neurosci 2011 146 2011; 14: 697–703.

| | 376 | 20. | Bock HH, Jossin Y, Liu P | P, Förster E, May | / P, Goffinet AM, | , et al. Phosphatidylinosit | ol 3 |
|--|-----|-----|--------------------------|-------------------|-------------------|-----------------------------|------|
|--|-----|-----|--------------------------|-------------------|-------------------|-----------------------------|------|

- 377 Kinase Interacts with the Adaptor Protein Dab1 in Response to Reelin Signaling and Is
- 378 Required for Normal Cortical Lamination *. J Biol Chem 2003; 278: 38772–38779.
- 379 21. Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, et al. Genetic Modulation of Tau
- 380 Phosphorylation in the Mouse. J Neurosci 2003; 23: 187–192.
- 381 22. Matsuki T, Zaka M, Guerreiro R, van der Brug MP, Cooper JA, Cookson MR, et al.
- 382 Identification of Stk25 as a Genetic Modifier of Tau Phosphorylation in Dab1-Mutant
- 383 Mice. PLoS One 2012; 7: e31152.
- 384 23. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction
- 385 captures nearly all common genetic risk for Alzheimer's disease. Neurobiol Aging
- 386 2017; 49: 214.e7-214.e11.
- 387 24. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-
- 388 analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ,
- tau, immunity and lipid processing. Nat Genet 2019 513 2019; 51: 414–430.
- 390 25. Frieden C, Garai K. Structural differences between apoE3 and apoE4 may be useful in
- 391 developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A 2012;
- **3**92 **109: 8913–8918**.
- 393 26. Abadesco AD, Cilluffo M, Yvone GM, Carpenter EM, Howell BW, Phelps PE. Novel
- 394 Disabled-1-expressing neurons identified in adult brain and spinal cord. Eur J Neurosci
- 395 2014; 39: 579–592.
- 396 27. Howell BW, Herrick TM, Cooper JA. Reelin-induced tryosine phosphorylation of
- 397 Disabled 1 during neuronal positioning. Genes Dev 1999; 13: 643.
- 398 28. Howell BW, Herrick TM, Hildebrand JD, Zhang Y, Cooper JA. Dab1 tyrosine
- 399 phosphorylation sites relay positional signals during mouse brain development. Curr

| 400 | Biol 2000; | 10: | 877–885. |
|-----|------------|-----|----------|
| | | | |

- 401 29. Rice DS, Sheldon M, D'Arcangelo G, Nakajima K, Goldowitz D, Curran T. Disabled-1
- 402 acts downstream of Reelin in a signaling pathway that controls laminar organization
- 403 in the mammalian brain. Development 1998; 125: 3719–3729.
- 404 30. Qiu S, Weeber EJ. Reelin signaling facilitates maturation of CA1 glutamatergic
- 405 synapses. J Neurophysiol 2007; 97: 2312–2321.
- 406 31. Ventruti A, Kazdoba TM, Niu S, D'Arcangelo G. Reelin deficiency causes specific
- 407 defects in the molecular composition of the synapses in the adult brain. Neuroscience
- 408 2011; 189: 32–42.
- 409 32. Pujadas L, Gruart A, Bosch C, Delgado L, Teixeira CM, Rossi D, et al. Reelin Regulates
- 410 Postnatal Neurogenesis and Enhances Spine Hypertrophy and Long-Term
- 411 Potentiation. J Neurosci 2010; 30: 4636–4649.
- 412 33. Rogers JT, Rusiana I, Trotter J, Zhao L, Donaldson E, Pak DTS, et al. Reelin
- 413 supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine
- 414 density. Learn Mem 2011; 18: 558–564.
- 415 34. Trotter J, Lee GH, Kazdoba TM, Crowell B, Domogauer J, Mahoney HM, et al. Dab1 Is
- 416 Required for Synaptic Plasticity and Associative Learning. J Neurosci 2013; 33: 15652–
- 417 15668.
- 418 35. Weeber EJ, Beffert U, Jones C, Christian JM, Förster E, David Sweatt J, et al. Reelin and
- 419 ApoE Receptors Cooperate to Enhance Hippocampal Synaptic Plasticity and Learning
- 420 *. J Biol Chem 2002; 277: 39944–39952.
- 421 36. Hoe H-S, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin Effects on
- 422 Amyloid Precursor Protein and ApoE Receptor 2 Trafficking and Processing *. J Biol
- 423 Chem 2006; 281: 35176–35185.

| 424 | 37. | Corder EH, S | aunders AM, | Strittmatter V | VJ, Schmechel | DE, (| Gaskell PC, | Small GW, | , et al. |
|-----|-----|--------------|-------------|----------------|---------------|-------|-------------|-----------|----------|
|-----|-----|--------------|-------------|----------------|---------------|-------|-------------|-----------|----------|

- 425 Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in
- 426 Late Onset Families. Science (80-) 1993; 261: 921–923.
- 427 38. Freudenberg-Hua Y, Li W, Davies P. Effects of Age, Sex, and Ethnicity on the
- 428 Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-
- 429 analysis. Front Med 2018; 0: 108.
- 430 39. Andrews SJ, Fulton-Howard B, Goate A. Interpretation of risk loci from genome-wide
- 431 association studies of Alzheimer's disease. Lancet Neurol 2020; 19: 326–335.
- 432 40. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New
- 433 insights into the genetic etiology of Alzheimer's disease and related dementias. Nat
- 434 Genet 2022 544 2022; 54: 412–436.
- 435 41. Jun G, Vardarajan BN, Buros J, Yu C-E, Hawk M V., Dombroski BA, et al.
- 436 Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region.
- 437 Arch Neurol 2012; 69: 1270–1279.
- 438 42. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al. Common
- 439 variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset
- 440 Alzheimer's disease. Nat Genet 2011 435 2011; 43: 436–441.
- 441 43. Zhou X, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo Q, et al. Non-coding variability at
- the APOE locus contributes to the Alzheimer's risk. Nat Commun 2019 101 2019; 10:
- 443 **1–16**.
- 444 44. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et
- 445 al. A TOMM40 variable-length polymorphism predicts the age of late-onset
- 446 Alzheimer's disease. Pharmacogenomics J 2010 105 2009; 10: 375–384.
- 447 45. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, et al.

| 448 | | Reduced Reelin Expression Accelerates Amyloid- β Plaque Formation and Tau |
|-----|-----|--|
| 449 | | Pathology in Transgenic Alzheimer's Disease Mice. J Neurosci 2010; 30: 9228–9240. |
| 450 | 46. | Pujadas L, Rossi D, Andrés R, Teixeira CM, Serra-Vidal B, Parcerisas A, et al. Reelin |
| 451 | | delays amyloid-beta fibril formation and rescues cognitive deficits in a model of |
| 452 | | Alzheimer's disease. Nat Commun 2014 51 2014; 5: 1–11. |
| 453 | 47. | Rice HC, Young-Pearse TL, Selkoe DJ. Systematic evaluation of candidate ligands |
| 454 | | regulating ectodomain shedding of Amyloid precursor protein. Biochemistry 2013; |
| 455 | | 52: 3264–3277. |
| 456 | 48. | Rossi D, Gruart A, Contreras-Murillo G, Muhaisen A, Ávila J, Delgado-García JM, et al. |
| 457 | | Reelin reverts biochemical, physiological and cognitive alterations in mouse models |
| 458 | | of Tauopathy. Prog Neurobiol 2020; 186: 101743. |
| 459 | 49. | Gao H, Tao Y, He Q, Song F, Saffen D. Functional enrichment analysis of three |
| 460 | | Alzheimer's disease genome-wide association studies identities DAB1 as a novel |
| 461 | | candidate liability/protective gene. Biochem Biophys Res Commun 2015; 463: 490– |
| 462 | | 495. |
| 463 | 50. | Botella-López A, Burgaya F, Gavín R, García-Ayllón MS, Gómez-Tortosa E, Peña- |
| 464 | | Casanova J, et al. Reelin expression and glycosylation patterns are altered in |
| 465 | | Alzheimer's disease. Proc Natl Acad Sci U S A 2006; 103: 5573–5578. |
| 466 | 51. | Muller T, Loosse C, Schrotter A, Schnabel A, Helling S, Egensperger R, et al. The AICD |
| 467 | | Interacting Protein DAB1 is Up-Regulated in Alzheimer Frontal Cortex Brain Samples |
| 468 | | and Causes Deregulation of Proteins Involved in Gene Expression Changes. Curr |
| 469 | | Alzheimer Res 2011; 8: 573–582. |
| 470 | 52. | Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, et al. Reelin Depletion in |
| 471 | | the Entorhinal Cortex of Human Amyloid Precursor Protein Transgenic Mice and |

| 472 | | Humans with Alzheimer's Disease. J Neurosci 2007; 27: 2727–2733. |
|-----|-----|--|
| 473 | 53. | Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The Disabled 1 |
| 474 | | Phosphotyrosine-Binding Domain Binds to the Internalization Signals of |
| 475 | | Transmembrane Glycoproteins and to Phospholipids. Mol Cell Biol 1999; 19: 5179– |
| 476 | | 5188. |
| 477 | 54. | Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of Cytosolic Adaptor Proteins |
| 478 | | with Neuronal Apolipoprotein E Receptors and the Amyloid Precursor Protein *. J Biol |
| 479 | | Chem 1998; 273: 33556–33560. |
| 480 | 55. | Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, et al. Mutagenesis |
| 481 | | Identifies New Signals for β -Amyloid Precursor Protein Endocytosis, Turnover, and the |
| 482 | | Generation of Secreted Fragments, Including A eta 42 *. J Biol Chem 1999; 274: 18851– |
| 483 | | 18856. |
| 484 | 56. | Howell BW, Herz J. The LDL receptor gene family: signaling functions during |
| 485 | | development. Curr Opin Neurobiol 2001; 11: 74–81. |
| 486 | 57. | Shinohara M, Tachibana M, Kanekiyo T, Bu G. Role of LRP1 in the pathogenesis of |
| 487 | | Alzheimer's disease: evidence from clinical and preclinical studies: Thematic Review |
| 488 | | Series: ApoE and Lipid Homeostasis in Alzheimer's Disease. J Lipid Res 2017; 58: |
| 489 | | 1267–1281. |
| 490 | 58. | Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function |
| 491 | | and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl |
| 492 | | Acad Sci U S A 2010; 107: 12011–12016. |
| 493 | 59. | Lane-Donovan C, Philips GT, Wasser CR, Durakoglugil MS, Masiulis I, Upadhaya A, et |
| 494 | | al. Reelin protects against amyloid β toxicity in vivo. Sci Signal 2015; 8. |
| 495 | 60. | Bar I, Tissir F, Lambert de Rouvroit C, De Backer O, Goffinet AM. The Gene Encoding |

- 496 Disabled-1 (DAB1), the Intracellular Adaptor of the Reelin Pathway, Reveals Unusual
- 497 Complexity in Human and Mouse *. J Biol Chem 2003; 278: 5802–5812.
- 498 61. D D, Hung K-Y, Tarn W-Y. RBM4 Modulates Radial Migration via Alternative Splicing of
- 499 Dab1 during Cortex Development. Mol Cell Biol 2018; 38.
- 500 62. Gao Z, Godbout R. Reelin-Disabled-1 signaling in neuronal migration: splicing takes
- 501 the stage. Cell Mol Life Sci 2012 7013 2012; 70: 2319–2329.
- 502 63. Yano M, Hayakawa-Yano Y, Mele A, Darnell RB. Nova2 Regulates Neuronal Migration
- 503 through an RNA Switch in Disabled-1 Signaling. Neuron 2010; 66: 848–858.
- 504 64. Howell BW, Gertler FB, Cooper JA. Mouse disabled (mDab1): a Src binding protein
- 505 implicated in neuronal development. EMBO J 1997; 16: 121–132.
- 506 65. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on
- 507 family history of Alzheimer's disease. Transl Psychiatry 2018 81 2018; 8: 1–7.
- 508

510 Figure legends

511

- 512 **Figure 1:** Manhattan plot for the genome-wide association study in *APOE*-ε4 homozygotes
- 513 with SNP MAF > 5%.



515

- 517 **Figure 2:** The cumulative risk of AD among *APOE*- ε 4 homozygous of the UK Biobank
- 518 participants, who carry 0, 1 or 2 risk alleles T the lead SNP (rs112437613) in DAB1.



- 521 **Figure 3.** Epistatic effect between *APOE*-ε4 and rs112437613 (*DAB1*) in the whole sample of
- 522 the UK Biobank aged 65+ (N=229,748). All log(odds ratio) values are with respect to the
- 523 baseline homozygote with no counted alleles at both loc. Orange/red bars have negative
- 524 values. All odds ratios are adjusted for age, sex and principal components.



525

526

- 528 **Figure 4.** REELIN-DAB1 signalling pathway based on studies in mouse neurons and brain
- 529 (human protein names are shown, created with BioRender.com, see BioRender's Academic
- 530 License publication licence in the Supplemental material). The pathway branches
- 531 downstream of the signalling complex. Branch 1 regulates the cell surface expression of
- 532 CDH2 (N-cadherin) and branch 2 regulates MAPT phosphorylation.



533 **Table 1:** Novel genome-wide significant SNPs in *DAB1*.

| | | | | Current Analysis | | | | | Previous LOAD GWAS [65] | | |
|-----|----------|-------------|--------------|------------------|------|------|------|----------------------|-------------------------|------|----------------------|
| CHR | BP | SNP | Closest gene | Effect/Alt | Freq | OR | SE | <i>p</i> -value | Effect/Alt | OR | <i>p</i> -value |
| 1 | 57625932 | rs17541203 | DAB1 | C/T | 0.07 | 2.19 | 0.14 | 2.4x10 ⁻⁸ | C/T | 0.98 | 4.8x10 ⁻¹ |
| 1 | 57643271 | rs197111 | DAB1 | T/C | 0.07 | 2.16 | 0.14 | 3.1x10 ⁻⁸ | T/C | 0.98 | 4.1x10 ⁻¹ |
| 1 | 57646630 | rs78921149 | DAB1 | T/C | 0.07 | 2.22 | 0.14 | 1.4x10 ⁻⁸ | T/C | 0.98 | 4.2x10 ⁻¹ |
| 1 | 57647715 | rs112437613 | DAB1 | T/C | 0.07 | 2.28 | 0.14 | 5.4x10 ⁻⁹ | T/C | 0.99 | 5.0x10 ⁻¹ |
| 1 | 57648856 | rs17115257 | DAB1 | G/T | 0.08 | 2.12 | 0.13 | 1.0x10 ⁻⁸ | G/T | 0.99 | 6.5x10 ⁻¹ |
| 1 | 57650410 | rs58359668 | DAB1 | T/C | 0.08 | 2.12 | 0.13 | 1.1x10 ⁻⁸ | T/C | 0.99 | 6.5x10 ⁻¹ |

534

535 CHR –chromosome; BP –base-pair position in build37; SNP –single nucleotide polymorphism, closest gene –genes were annotated with

536 assembly hg19; effect/non-effect –effect and non-effect alleles; freq- frequency of reference allele in the UK Biobank APOE-E4 homozygotes

537 individuals; OR, SE, p-value –odds ratio, standard error and p-value of the current and previous reported AD GWAS association studies; GWAS

538 -reference of the corresponding GWAS study

Table 2. Results of the gene-based analyses for the genes in the DAB1-RELN pathway

accounting for the number of SNPs and the LD structure for each gene using MAGMA

software.

| GENE | CHR | START | STOP | N SNPs | p-value |
|---------|-----|-----------|-----------|--------|---------|
| AKT1 | 14 | 105235686 | 105262080 | 76 | 0.0044 |
| CDH2 | 18 | 25530930 | 25757445 | 471 | 0.164 |
| CRK | 17 | 1324647 | 1359561 | 90 | 0.660 |
| CRKL | 22 | 21271714 | 21308037 | 86 | 0.847 |
| CTNND1 | 11 | 57520756 | 57586652 | 86 | 0.157 |
| DAB1 | 1 | 57460453 | 58716211 | 3496 | 0.004 |
| FYN | 6 | 111981535 | 112194655 | 538 | 0.456 |
| RAPGEF1 | 9 | 134452157 | 134615364 | 393 | 0.404 |
| GSK3B | 3 | 119540800 | 119813264 | 407 | 0.840 |
| PDK1 | 2 | 173420101 | 173490351 | 200 | 0.546 |
| PDK2 | 17 | 48172101 | 48188733 | 53 | 0.143 |
| РІКЗСА | 3 | 178866311 | 178952500 | 203 | 0.033 |
| RELN | 7 | 103112231 | 103629963 | 1987 | 0.0069 |
| RAP1A | 1 | 112162405 | 112256807 | 307 | 0.00025 |
| SRC | 20 | 35973088 | 36033835 | 133 | 0.546 |
| VLDLR | 9 | 2621679 | 2654485 | 103 | 0.158 |
| YES1 | 18 | 721592 | 812327 | 232 | 0.809 |
| LRP8 | 1 | 53708036 | 53793821 | 194 | 0.842 |
| STK25 | 2 | 242434122 | 242449145 | 45 | 0.161 |

GENE –gene annotation with assembly hg19; CHR- chromosome; START, STOP – start and stop base-pair positions for genes; N SNPs- the number of SNPs in the analysis, p-value for the gene-based association test.